Loading...
•
Jun 30, 2024
Xenon Pharmaceuticals Q2 2024 Earnings Report
Reported financial results for the second quarter ended June 30, 2024.
Key Takeaways
Xenon Pharmaceuticals reported a net loss of $57.9 million for the quarter ended June 30, 2024, compared to a net loss of $47.5 million for the same period in 2023. The company's cash and cash equivalents and marketable securities were $850.6 million as of June 30, 2024.
Phase 3 epilepsy program progressing with X-TOLE2 topline FOS data anticipated in H2 2025.
MDD program on track with Phase 3 study expected to initiate in H2 2024.
Multiple Kv7 and Nav1.7 candidates progressing towards development with INDs expected in 2025.
Cash and cash equivalents and marketable securities were $850.6 million as of June 30, 2024.
Forward Guidance
Xenon anticipates having sufficient cash to fund operations into 2027.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...